<DOC>
	<DOC>NCT01816815</DOC>
	<brief_summary>Effects of BAY1002670 on bleeding pattern: non-bleeding rate; on endometrium; on ovarian function; return of menstrual bleeding after treatment; safety and tolerability; PK/PD (pharmacokinetic/pharmacodynamic) relationship</brief_summary>
	<brief_title>Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<criteria>Healthy female subjects Sterilized by tubal ligation Age 1845 years Body mass index (BMI) at screening: ≥ 18 and ≤ 32 kg/m² At least 3 consecutive regular menstrual cycles with a cycle length of 24 35 days before first screening examination according to the subject's history Absence of clinically relevant abnormal findings in the pretreatment endometrial biopsy Regular use of medicines (incl. anabolics) Incompletely cured preexisting diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal Amenorrhea for more than 3 months within the last 6 months before the first screening examination Lacking suitability for frequent transvaginal ultrasonography (TVU) examinations Clinically relevant findings (e.g. blood pressure, electrocardiogram [ECG], physical and gynecological examination, laboratory examination)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>PK/PD</keyword>
	<keyword>BAY1002670</keyword>
</DOC>